How MAT® Works

MAT® PHYSIOLOGY 

MAT® treatment (metabolic activation therapy) involves delivering insulin intravenously in a pulsatile fashion using a special pump over a six to seven hour period. 

Pumps used in the MAT®   treatment procedure are not the typical insulin pumps in common use for diabetes.  The usual insulin pump delivers insulin subcutaneously.   Several FDA approved pumps for intravenous use can be used for MAT® treatment. 

The pulses deliver a higher, more physiologic concentration of insulin to the liver than are delivered by traditional sub-cutaneous injections. This higher level of insulin available to the liver with metabolic activation therapy stimulates liver cells to synthesize glucokinase and other insulin-dependent enzymes necessary for normal dietary glucose processing and homeostasis.

The Diabetic Liver

In “normal” individuals(without diabetes), insulin levels measured in the portal vein to the liver can range from 200 microU/ml* to 1,000 microU/ml immediately following a meal. Unfortunately, the insulin levels of type I diabetes patients on standard subcutaneous insulin therapy only reach a concentration of 15 microU/ml to 20 microU/ml at the portal vein. These lower insulin levels are insufficient to activate and maintain optimal hepatic glucose processing.

In contrast to usual insulin therapy, MAT®  treatment  pulses appear to enhance the liver’s ability to store, mobilize and utilize glucose. The higher level of insulin available to the liver with MAT®  treatment  stimulates liver cells to synthesize glucokinase and other insulin-dependent enzymes necessary for normal dietary glucose processing and homeostasis. 

In Type 1 diabetes MAT® treatment Conventional Insulin Therapy
Insulin injection site Directly into a vein Subcutaneous tissue
Pattern of insulin delivery to the liver RapidlyPulses – sharp spikes SlowlyGradual rise and fall
Level of insulin  available to the liver. Very High  (200-1000 microU/ml)* Very Low(15-20 microU/ml)*
  * microU /ml = one millionth of a Unit of insulin per milliliter

 Other Tissues

At times of reduced tissue oxygen, such as when circulation is decreased,  MAT® treatment (by enabling the production of energy from glucose) may permit heart, skeletal muscle, skin, and other organs to function more normally and even to repair damage and heal.

Because the insulin pulses are “seen” by the entire body, not just the liver, the pulses may alter and improve the metabolism of other organs besides the liver. In both normal and diabetic individuals, most organs rely on the metabolism of fatty acids for 70 percent to 80 percent of their fuel. However, the breakdown of fatty acids requires more oxygen at the cellular level than the breakdown of glucose for a given energy output. Pulsed insulin therapy may permit organs to use glucose as an energy source to a significantly greater extent than usual (due to increased pyruvate dehydrogenase activity) and thus decrease the organ’s oxygen requirements.

References

Note: In the older articles MAT®  treatment was referred to by other names including: chronic intermittent intravenous insulin therapy (CIIIT), metabolic activation therapy (MAT),  pulsatile insulin,  pulse insulin therapy (PIT), pulsatile intravenous insulin therapy (PIVIT) and hepatic activation.  .

Review Articles

1.  Chronic intermittent intravenous insulin therapy: a new frontier in diabetes therapy Aoki TT, Grecu EO, Arcangeli MA, Benbarka MM, Prescott P, Ahn JH. Diabetes Technol Ther. 2001 Spring;3(1):111-23. Review.

2.  Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.  Aoki TT, Benbarka MM, Okimura MC, Arcangeli MA, Walter RM Jr, Wilson LD, Truong MP, Barber AR, Kumagai LF.  Lancet. 1993 Aug 28;342(8870):515-8.

3. Type I diabetes: The ‘sleeping liver’ hypothesis and its clinical implications. Aoki TT, Benbarka MM. Modern Medicine 1992 60:73-76.

4. Type I diabetes: An intensive approach to controlling blood glucose levels. Aoki TT, Benbarka MM. 1992 Modern Medicine 60:88-103.

Nephropathy

Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy.  Dailey GE, Boden GH, Creech RH, Johnson DG, Gleason RE, Kennedy FP, Weinrauch LA, Weir M, D’Elia JA.  Metabolism. 2000 Nov;49(11):1491-5.

Effect of intensive insulin therapy on progression of overt nephropathy in patients with type 1 diabetes mellitus.  Aoki TT, Grecu EO, Gollapudi GM, Barber AR, Arcangeli MA, Benbarka MM, Prescott P, Meisenheimer R. Endocr Pract. 1999 Jul-Aug;5(4):174-8.

A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria.  Weinrauch LA, Burger AJ, Aepfelbacher F, Lee AT, Gleason RE, D’Elia JA.  Metabolism. 2007 Nov;56(11):1453-7.

Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus.   Weinrauch LA, Sun J, Gleason RE, Boden GH, Creech RH, Dailey G, Kennedy FP, Weir MR, D’Elia JA.      Metabolism. 2010 Oct;59(10):1429-34. Epub 2010 Mar 1.

Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit.Weinrauch LA, Bayliss G, Gleason RE, Lee AT, D’Elia JA.  Metabolism. 2009 Apr;58(4):488-91.

Hypertension

Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy.  Aoki TT, Grecu EO, Prendergast JJ, Arcangeli MA, Meisenheimer R.  Diabetes Care. 1995 Sep;18(9):1260-5.

Effect of intensive insulin therapy on abnormal circadian blood pressure pattern in patients with type I diabetes mellitus  Aoki TT, Grecu EO, Arcangeli MA, Meisenheimer R.Online J Curr Clin Trials. 1995 Dec 15;Doc No 199:

Hypotension  

Chronic intermittent intravenous insulin therapy corrects orthostatic hypotension ofdiabetes  Aoki TT, Grecu EO, Arcangeli MA.Am J Med. 1995 Dec;99(6):683-4.

Hypoglycemia

Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.  Aoki TT, Benbarka MM, Okimura MC, Arcangeli MA, Walter RM Jr, Wilson LD, Truong MP, Barber AR, Kumagai LF.  Lancet. 1993 Aug 28;342(8870):515-8.

Cardiology

Reversal of severe nonischemic dilated cardiomyopathy by intensive intravenous insulin  therapy in a patient with NIDDM. Aoki TT, Grecu EO, Arcangeli MA. J Investigative Med. 1996  Jan; 44(1): 126A

Obstetrics

The effect of chronic intermittent intravenous insulin therapy on pregnancy outcome in insulin dependent diabetes mellitus. Field N, Boe N, Gilbert W, Benbarka M, Aoki T.  Journal Soc. Gynecol. Invest. 1997; 4(1, supplement): 196A.

Quality of Life

Measurement of health status in diabetic patients: diabetes impact measurement scales.Hammond GS, Aoki TT.  Diabetes Care 1992; 15: 469-477.

Physiology /Biochemistry

IGF-1 and IGFBP-1 blood levels in type 1 diabetes mellitus on intensive intravenous insulin therapy.  Aoki TT, Grecu EO.  J Invest Med, 1999; 47(2) 78 A.  (Abstract)

Role of muscle in CO2 production after oral glucose administration in man.   Meistas MT, Vlachokosta FV, Gleason RE, Arcangeli M, Aoki TT.  Diabetes. 1985 Oct;34(10):960-3.

Evidence for restoration of hepatic glucose processing in type I diabetes mellitus.  Aoki TT, Vlachokosta FV, Foss MC, Meistas MT.  J Clin Invest. 1983 Apr;71(4):837-9.

Restoration of glucose homeostasis in insulin-dependent diabetic subjects. An inducible process.  Foss MC, Vlachokosta FV, Cunningham LN, Aoki TT.  Diabetes. 1982 Jan;31(1):46-52.